Clinical trial
An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, C-1803, or C-1808 and a Dosing Suspension Safety Evaluation
NCT00297232 is registered in ClinicalTrials.gov with Biogen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, C-1803, or C-1808 and a Dosing Suspension Safety Evaluation
- Lead sponsor
- Biogen
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- March 31, 2006
- Completion date
- April 30, 2014
- Enrollment
- 1,094 (actual)
- Sites
- 112
Conditions
As the registry lists them; a condition with its own page is linked.
relapsing-remitting multiple sclerosis